Magnesium Blood Glucose Randomized Trial: What the Evidence Says

Quick Answer

Magnesium Blood Glucose Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Pre-diabetes mellitus (Pre-DM), a high-risk glycemic state for progression to type 2 diabetes (T2DM) and cardiovascular disease, imposes a substantial global health burden. [Yang Jingxin (2026); evidence level 2]
• Substantial epidemiological evidence consistently links lower dietary magnesium intake and hypomagnesemia to an increased risk of both pre-diabetes and T2DM. [Yang Jingxin (2026); evidence level 2]
• Epidemiological data consistently demonstrate that low dietary Mg intake and low serum Mg are independently associated with hypertension, coronary artery calcification, peripheral arterial disease (PAD), stroke, and cardiovascular mortality. [Yoon Yonghyun (2026); evidence level 4]
• Based on these criteria and the conceptual scope of this narrative review, the most relevant mechanistic, translational, epidemiological, clinical, guideline, and nutritional reference sources were incorporated into the final narrative synthesis. [Yoon Yonghyun (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For magnesium blood glucose randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Yang Jingxin (2026). Oral magnesium supplementation improves glycemic control in older Chinese adults with pre-diabetes and hypomagnesemia: a randomized controlled trial. DOI: 10.3389/fnut.2026.1765308. PMCID: PMC12932175. PMID: 41756632. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12932175/
• Yoon Yonghyun (2026). Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain. DOI: 10.3390/nu18111675. PMCID: PMC13257608. PMID: 42280320. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13257608/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.